Recombinant antigen TmpA for Treponema pallidum

CATALOG NUMBER: RAG0073


DESCRIPTION: the TmpA recombinant protein has been prepared by expressing the corresponding gene which codifies the mature membrane protein of 44.5 kDa of the spirochete Treponema pallidum.

PRESENTATION: liquid protein solution

SOURCE: Escherichia coli

MOLECULAR WEIGHT: determined by SDS-PAGE, the protein band is between molecular markers of 66,200 and 45,000 Da, while relative molecular mass calculated from amino acid sequence is 43488.86 Da.

BATCH COMPOSITION:

<table>
<thead>
<tr>
<th>COMPONENTS</th>
<th>COMPOSITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>his-TmpA</td>
<td>recombinant antigen with a his-tag in its N-terminus</td>
</tr>
<tr>
<td>Storage buffer</td>
<td>20 mM phosphate buffer pH 8, 0.15 M NaCl, 0.1% polyoxyethylene (10) tridecyl ether</td>
</tr>
</tbody>
</table>

QUALITY CONTROL:

1. PROTEIN CONCENTRATION DETERMINED ESPECTROPHOTOMETRICALLY

\[
\text{OD}_{280} = 0.780 \\
\text{A 0.1 % (} = 1 \text{ g/l}) = 0.403
\]

CONCENTRATION*: 1.93 mg/ml

* The measurement of the protein concentration has been performed with the theoretical extinction coefficient of the recombinant protein obtained from Gill and vonHippel, 1989

2. PURITY CONTROL IN SDS-PAGE: 12.5%

Figure 1. SDS-PAGE analysis (12.5%) of 1 μl of recombinant TmpA. Purity is > 95% as determined by gel electrophoresis.

3. TITRATION CURVE BY AN ELISA ASSAY

The titer has been suggested in reference to an "in-house" ELISA kit performed at Rekom Biotech over the first lot obtained. Assays were performed by using positive and negative syphilis specimen sera pre-validated with ELISA (Abbott: Architeck); TPHA (Spin React) and RPR (BectonDickinson).

Each end user should carry out his own titration for his particular application.

Figure 2. In this plot, the optical density at 450/620 nm for positive (blue) and negative (gray) sera are compared for each concentration of the recombinant antigen. An appropriate statistical test of significance for the comparison of means between both groups, the Welch’s test, is employed. Eligible concentrations for the use of the antigen should present statistically significant differences between positive and negative sera. This happens when the intervals at the top do not overlap and, equivalently, when the p-value at the bottom is below 0.05. In the present figure, all p-values are below 0.05 and thus the intervals do not overlap. Therefore, any of the showed concentrations can be used to distinguish between positive and negative sera.

4. ABSENCE OF PRECIPITATION AFTER A FREEZING AND THAWING CYCLE: ok

LOT SPECIFICATIONS:

1. CONCENTRATION: 1.93 mg/ml

2. TOTAL QUANTITY PER ALIQUOT: 1 mg

3. TOTAL VOLUME PER ALIQUOT: 0.52 ml

4. SUGGESTED TITER BY ELISA: up to 1:3,860, which corresponds to 0.5 μg/ml of protein concentration in plates for IgG detection.

5. STORAGE: Protein is shipped with dry ice. Upon arrival, it should be aliquoted in order to avoid repeated freezing and thawing cycles and stored at -20ºC to -80ºC

6. APPLICATIONS: ELISA and Western blot assays. Where this product has not been tested for use in a particular...
7. OBSERVATIONS: proteins should be maintained frozen at high concentrations. The dilution to be performed for ELISA assays should be made with a small quantity of protein, the same day of the experiment. In order to defrost the protein, maintain the aliquot at 25ºC without shaking to avoid aggregation. Prior making test dilutions and after defrosting the protein, is recommended to remove possible protein aggregates by centrifuging the stock solution, avoiding alterations in the immobilization of the biomolecule to the solid surface.

RELATED PRODUCTS:

BIBLIOGRAPHY:


Important Notes: During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 µl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the containers cap.

Although recombinant antigens are expressed in non-pathogenic E. coli and bacterial integrity is destroyed during purification, the antigen preparation should be handled as potentially infectious.

FOR RESEARCH AND COMMERCIAL USE IN VITRO: not for human in vivo or therapeutic use.